Tevogen Bio (NASDAQ:TVGN) Announces Quarterly Earnings Results

Tevogen Bio (NASDAQ:TVGN) released its quarterly earnings results on Friday. The company reported ($0.03) EPS for the quarter, Zacks reports.

Tevogen Bio Stock Performance

TVGN stock traded down $0.03 during mid-day trading on Friday, hitting $0.42. The company had a trading volume of 425,173 shares, compared to its average volume of 1,181,668. The firm has a market cap of $82.05 million, a PE ratio of -2.20 and a beta of -0.86. Tevogen Bio has a 12 month low of $0.42 and a 12 month high of $1.92. The stock’s fifty day moving average price is $0.70 and its two-hundred day moving average price is $0.97.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently raised its stake in Tevogen Bio stock. Bridgeway Capital Management LLC raised its position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) by 66.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 82,500 shares of the company’s stock after purchasing an additional 33,000 shares during the period. Bridgeway Capital Management LLC’s holdings in Tevogen Bio were worth $65,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analyst Weigh In

TVGN has been the subject of several recent analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Tevogen Bio in a research note on Thursday, September 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.00.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.